• where experts go to learn about FDA
  • Hyman Phelps McNamara

    • Coming Clean with DEA: No Good Deed Goes UnpunishedNovember 21st, 2013

       By John A. Gilbert & Delia A. Stubbs – In a decision published this week, DEA denied an application for a pharmacy registration on the basis that the owner-pharmacist had previously ignored “red flags” and generally failed to exercise her corresponding responsibility in filling prescriptions.  Wheatland …

    • DEA Releases 2013 Drug Threat Assessment SummaryNovember 20th, 2013

      By Karla L. Palmer – On Monday, November 18, 2013, DEA released the 2013 National Drug Threat Assessment Summary, which provides an assessment of the threat posed to the United States by trafficking and abuse of illicit substances and non-medical use of controlled prescription drugs.  The …

    • Along with the Track and Trace Legislation, Senate Passes the Compounding “Drug Quality and Security Act”: Now Awaiting President Obama’s SignatureNovember 19th, 2013

      By Karla L. Palmer –  As reported here yesterday on the track and trace provisions, after many months of legislative maneuvering and various iterations emanating from both the House and Senate, the Senate passed without amendment and by voice vote H.R. 3204 – the “Drug Quality …

    • Hyman, Phelps & McNamara, P.C. Names Two New DirectorsNovember 19th, 2013

      Hyman, Phelps & McNamara, P.C. is very pleased to announce that Larry K. Houck and Riëtte van Laack, PhD have been named Directors of the firm.  Mr. Houck’s practice area encompasses controlled substances and regulated chemicals as well as state licensing and registration compliance issues.  …

    • ACI’s Legal, Quality, Regulatory, and Compliance Forum on Current Good Manufacturing PracticesNovember 19th, 2013

      The American Conference Institute will be holding its inaugural forum oncurrent Good Manufacturing Practices (“cGMPs”) in Washington, D.C. from Thursday, January 23 to Friday, January 24, 2014.  A copy of the conference program can be obtained here.  Hyman, Phelps & McNamara, P.C.’s Douglas B. Farquhar …

    • Can It Be True? Has Congress Finally Tracked Down a Federal Track-and-Trace System?November 18th, 2013

      By Jessica A. Ritsick & William T. Koustas – Over 25 years ago, the Prescription Drug Marketing Act ("PDMA") was passed.  The PDMA called for implementation of a national system to follow prescription drugs through the supply chain.  After years of talking about it (see here), …

    • FSIS Issues Final Rule Expanding Category of Labeling That Does Not Require Prior ApprovalNovember 18th, 2013

      By Riëtte van Laack – On November 7, 2013, the Food Safety and Inspection Service (FSIS) amended its prior label approval system regulations to expand the circumstances in which certain types of labels and labeling are generically approved and do not need specific FSIS approval.  Under the …

    • HDMA’s 2013 Track-and-Trace Conference: Right Here Waiting for H.R. 3204November 17th, 2013

      By Jessica A. Ritsick & William T. Koustas – At this year’s Health Care Distribution Management Association (HDMA) annual track-and-trace conference, most minds were focused on one thing: the potential passage of H.R. 3204, the Drug Quality and Security Act, which would mandate a uniform, national, interoperable electronic …

    • FDLI Presents Webinar on US and EU Regulation of Health-Related Claims for FoodsNovember 17th, 2013

      On November 20th, the Food and Drug Law Institute ("FDLI") will present a webinar on the regulatory requirements that apply to health-related claims for foods.  Hyman, Phelps & McNamara, P.C.'s Ricardo Carvajal will discuss requirements applicable in the U.S.  Vicente Rodriguez, current president of the …

    • Personalized Medicine: FDA Says It Is ReadyNovember 14th, 2013

      By Allyson B. Mullen –  For many individuals, a diagnosis, be it life threatening or chronic, is scary.  However, the trial and error process that can follow the diagnosis in order to find a therapy (e.g., drug, device and/or biologic) that works best for the patient …

    • FDA Takes Aim at a Financial Community Broadcast in New Warning LetterNovember 13th, 2013

      By Dara Katcher Levy – A new Warning Letter issued by FDA’s Office of Prescription Drug Promotion (OPDP) suggests that FDA may want a new fight when it comes to the issue of that pesky First Amendment and the interplay with FDA-regulated products.  In a November 8, …

    • FDA Proposes a Rule that Would Undercut Generic Drug PreemptionNovember 12th, 2013

      By Jennifer M. Thomas – The generic drug industry has waited with bated breath since, as we reported here and here, FDA signaled that it was “considering a regulatory change that would allow generic manufacturers, like brand-name manufacturers, to change their labeling in appropriate circumstances.”  See …

    • Former Novo Nordisk General Counsel James C. Shehan Joins Hyman, Phelps & McNamara, P.C.November 11th, 2013

      Hyman, Phelps & McNamara, P.C. is pleased to announce that James C. Shehan has joined the firm as Of Counsel.  Previously, Mr. Shehan served for 19 years as Novo Nordisk Inc.’s General Counsel and Corporate Vice President of Legal, Government and Quality.  His extensive experience …

    • FDA Proposes to Phase Out Use of Partially Hydrogenated OilsNovember 11th, 2013

      By Etan J. Yeshua – The Food and Drug Administration last week initiated a process that could prohibit the sale of partially hydrogenated oils (PHOs), as well as food products containing industrially manufactured PHOs, such as certain baked goods, microwave popcorn, frozen pizzas, frostings, and …

    • Trends in Personalized MedicineNovember 10th, 2013

      An article published in the current edition of Regulatory Focus, the flagship publication of the Regulatory Affairs Professionals Society (RAPS), and authored by Hyman, Phelps & McNamara, P.C.’s Alexander J. Varond discusses the recent trends and developments in personalized medicine, including FDA’s current thinking and …